Search research articles

Related Concept Videos

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Home
Assessing Cd36 And Cd47 Expression Levels In Solid Tumor Indications To Stratify Patients For Vt1021 Treatment.

Home
Assessing Cd36 And Cd47 Expression Levels In Solid Tumor Indications To Stratify Patients For Vt1021 Treatment.

Related Experiment Video

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment.

Suming Wang¹, Victor Zota², Melanie Y Vincent²

¹Vigeo Therapeutics, Cambridge, MA, USA. Suming.Wang@vigeotx.com.

NPJ Precision Oncology

|December 3, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A new cancer therapy, VT1021, boosts thrombospondin-1 (TSP-1) in tumor-infiltrating myeloid-derived suppressor cells (MDSCs). CD36 and CD47 are identified as key biomarkers for patient selection and predicting treatment success.

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

Oncology
Immunology
Biomarker Discovery

Background:

Most cancer patients lack specific biomarkers for targeted therapies.
The tumor microenvironment (TME) plays a critical role in cancer progression and treatment resistance.

Purpose of the Study:

To develop a novel therapeutic agent, VT1021, targeting the TME.
To identify biomarkers for patient stratification and prognosis in response to VT1021 treatment.

Main Methods:

VT1021 was developed to induce thrombospondin-1 (TSP-1) expression.
Myeloid-derived suppressor cells (MDSCs) recruited to the TME were investigated.
CD36 and CD47 were analyzed as potential biomarkers.

Main Results:

VT1021 successfully induced TSP-1 expression in MDSCs within the TME.

CD36 and CD47 were identified as dual biomarkers.

These biomarkers showed potential for patient stratification and prognosis.

Conclusions:

VT1021 represents a promising therapeutic strategy by modulating the TME.
CD36 and CD47 serve as valuable tools for personalizing VT1021 cancer therapy.